Results 131 to 140 of about 3,081 (193)

Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report. [PDF]

Ther Adv Med Oncol
Sunder-Plassmann V, Kiesewetter B, Raderer M.   +2 more
europepmc   +1 more source

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies. [PDF]

Mol Ther Oncol
Ni Q, Rui L.
europepmc   +1 more source

Infectious adverse events associated with novel Bruton tyrosine kinase (BTK) inhibitors in adults with chronic lymphocytic leukaemia: A meta-analysis of randomized controlled trials. [PDF]

Br J Haematol
Janc JJ, Wróbel T, Feliniak N, Kalicińska E.   +3 more
europepmc   +1 more source

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry. [PDF]

Eur J Haematol
Kutsch N, Ligtvoet R, Robrecht S, Linde H, Illmer T, Dörfel S, Lipke J, Aldaoud A, Schlag R, Dengler J, Al-Sawaf O, Langerbeins P, Cramer P, Hallek M, Eichhorst B, Fischer K, Fink A.   +16 more
europepmc   +1 more source

Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025. [PDF]

Exp Hematol Oncol
Liang Y, Deng X, Wang Z, Xie C, Zheng L, Huang H, Yin S, Huang H.   +7 more
europepmc   +1 more source

Analysis of factors influencing SARS-CoV-2 infection and outcomes in patients with chronic lymphocytic leukemia during the burst of COVID-19 epidemic. [PDF]

BMC Cancer
Wang J, Wang S, Xu F, Hu H, Liu YP, Liang XG, Feng GP, Chen B.   +7 more
europepmc   +1 more source

Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control. [PDF]

Cancer Biol Ther
Lyu LW, Yao N, Liu ZX, Wang YY, Li J, Zhou HB, Li LH, Li ZL, Wang L.   +8 more
europepmc   +1 more source

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis. [PDF]

Cureus
Singh M, Podder D, Jacoby AP, Saha S, Chatterji S, Ghosh S, Chattopadhyay D, Kumar J, Nag A, Javed R, Rath A, Chakraborty S, Demde R, Ghosh P, Parihar M, Zameer L, Goel G, Bhattacharya S, Majumder P, Chandy M, Nair R.   +20 more
europepmc   +1 more source

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study. [PDF]

Blood Adv
Autore F, Tedeschi A, Benevolo G, Danesin N, Giannarelli D, Rizzi R, Cencini E, Mattiello V, Ferrarini I, Pasquale R, Del Giudice I, Ferrari A, Bullo M, Rossini B, Motta M, Marino D, Innocenti I, Stirparo L, Petrilli D, Musto P, Peri V, Zamprogna G, Hohaus S, Frustaci AM, Piazza F, Ferrero S, Laurenti L.   +26 more
europepmc   +1 more source

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. [PDF]

Am J Hematol
Smith SD, Sundaram S, Giri S, Ness A, Wang Y, Gopal AK, Pang Y, Tatoian ET, Grossfeld T, Lynch RC, Warren EH, Nowakowski GS, Park SI.   +12 more
europepmc   +1 more source